Are there any long-term productivity impacts linked to screwworm prevention measures OpenEvidence
This OpenEvidence evidence synthesis provides a comprehensive deep‑dive into the New World screwworm (Cochliomyia hominivorax) as it relates to the United States. It begins with a detailed description of the fly’s biology and obligate parasitic life cycle, emphasizing female oviposition behavior and larval tissue destruction. The document then chronicles the historic eradication campaign launched in the 1950s, highlighting the development and deployment of the sterile insect technique (SIT) that eliminated reproducing populations from the U.S. by the 1960s and established a permanent sterile‑fly barrier along the Panama‑Colombia border. Recent re‑emergence events in the Florida Keys (2016‑2017), Panama (2023), Costa Rica (2023), and Mexico (2024‑2025) are summarized, together with bioclimatic risk‑modeling that identifies Texas and Florida as the highest‑risk states under climate‑change scenarios. The synthesis reviews advances in surveillance, including real‑time PCR, SNP panels, and a chromosomal‑scale genome that enable rapid molecular identification and source tracking. Clinical relevance for human myiasis is covered with a step‑by‑step management algorithm (mechanical removal, surgical debridement, oral ivermectin 200 µg/kg, antibiotics, and reporting). Veterinary prevention measures are catalogued, comparing macrocyclic lactones (doramectin, ivermectin, abamectin), topical insecticides (fipronil, dichlorfenthion, dicyclanil), organophosphates, and newer agents (spinosad, nitenpyram, afoxolaner). Emerging resistance to avermectins and organophosphates is highlighted, along with pharmacokinetic‑pharmacodynamic evidence of treatment failures. The document evaluates long‑term productivity impacts of screwworm control, balancing the massive economic dividend of eradication against negative effects such as castration‑related growth penalties, anthelmintic resistance, dung‑beetle ecosystem loss, and drug‑residue trade constraints. Environmental and ecotoxicological consequences of ivermectin and fipronil residues on non‑target insects, soil, water, and dung‑beetle services are detailed. Finally, future directions are discussed, including transgenic male‑only strains, radiation‑based SIT improvements, and targeted selective treatment (TST) protocols to sustain control while minimizing productivity losses. The synthesis is richly referenced (Scientific Reports, J Med Entomology, AJTMH, BMC Biology, Veterinary Parasitology, etc.) and includes prompts for deeper exploration of ivermectin resistance and clinical protocols.
Topics
New World Screwworm Biology and Obligate Parasitic Life Cycle
Key biological features of Cochliomyia hominivorax, including female attraction to wounds, egg clutch size, larval tissue invasion, and rapid population growth dynamics.
Veterinary Prevention Strategies: Drug Classes, Efficacy, and Emerging Resistance
Comparison of macrocyclic lactones (doramectin, ivermectin, abamectin), topical insecticides (fipronil, dichlorfenthion, dicyclanil), organophosphates, and newer agents (spinosad, nitenpyram, afoxolaner), with data on prophylactic and curative efficacy and documented resistance mutations.
Long‑Term Productivity Impacts of Screwworm Prevention Measures
Economic analysis of the eradication dividend versus negative productivity effects: castration‑related growth penalties, anthelmintic resistance costs, dung‑beetle ecosystem service loss, and drug‑residue trade/food‑safety constraints.